Adults and Children 12 yr of age and older: PO 125 to 500 mg twice daily. IV / IM 750 mg to 1.5 g every 8 h.
Children younger than 12 yr of age: PO 125 to 250 mg twice daily.
Infants and Children older than 3 mo of age: IV / IM 50 to 150 mg/kg/day (not to exceed adult dose) in equally divided doses every 6 to 8 h.
Adults and Children 12 yr of age and older: IV / IM Up to 3 g every 8 h.
Infants and Children 3 mo to 12 yr of age: IV / IM 200 to 240 mg/kg/day in divided doses every 6 to 8 h.
Adults and Children 12 yr of age and older: PO 1 g as single dose. IM 1.5 g as single dose.
Adults: IV / IM 1.5 g 30 min to 1 h before surgery then 750 mg every 8 h for duration of surgery.
Inhibits mucopeptide synthesis in bacterial cell wall.
Hypersensitivity to cephalosporins.
Use Cautiously in:
GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
GU: Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
HEPA: Hepatic dysfunction; abnormal LFT results.
OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis, thrombophlebitis, and pain at injection site.
Increased risk of nephrotoxicity with parenteral cefuroxime.
Inhibition of renal excretion of cefuroxime.
Do not add aminoglycosides to cefuroxime solutions because inactivation of both drugs may result; administer at separate sites if concurrent therapy is indicated.
Therapeutic Classification: anti-infectives
Pharmacologic Classification: second generation cephalosporins
Absorption: Well absorbed after oral and IM administration; IV administration results in complete bioavailability.
Distribution: Widely distributed. Penetrates into CSF with IV administration. Crosses the placenta and enters breast milk in low concentrations.
Protein Binding: 50%.
Metabolism/Excretion: Excreted primarily unchanged in the urine.
Half-life: 1–2 hr (increased in renal impairment).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal